Radiopharmaceuticals as orphan drugs

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Development
• Rare Diseases

Background:

• Rare diseases affect fewer than 200,000 people in the U.S., leading to limited economic incentive for drug development.
• These conditions are often misdiagnosed or undiagnosed due to unfamiliarity with their symptoms.
• Rare disorders are also known as orphan diseases.

Purpose of the Study:

• To inform nuclear medicine scientists and physicians about incentives for developing orphan radiopharmaceuticals.
• To highlight the potential of nuclear medicine in addressing unmet needs in rare disease diagnosis and treatment.
• To guide healthcare professionals on accessing information regarding orphan diseases and related radiopharmaceuticals.

Main Methods:

• Review of legislation providing incentives for orphan drug development.
• Exploration of the role of nuclear medicine in creating diagnostic and therapeutic radiopharmaceuticals.
• Identification of information resources for orphan diseases and orphan radiopharmaceuticals.

Main Results:

• Legislation exists to incentivize the development of orphan drug products.
• Nuclear medicine offers a pathway for creating novel orphan radiopharmaceuticals.
• Information resources are available to support the development and application of orphan radiopharmaceuticals.

Conclusions:

• Nuclear medicine scientists can utilize incentives to develop orphan radiopharmaceuticals for rare diseases.
• Enhanced knowledge of orphan diseases and radiopharmaceuticals can improve patient care.
• This approach addresses the diagnostic and therapeutic challenges posed by rare conditions.